Research news
Join Luisa Torsi as she discusses single-molecule detections at point-of-care during her webinar.
Imagine a future where diseases can be detected at their earliest stages, even before symptoms appear.
This is no longer a dream but a revolutionary step forward in healthcare. And it's made possible by the groundbreaking SiMoT (Single-Molecule-with-a-large-Transistor) bioelectronic platform.
Join us for this insightful webinar to discover how this technology is set to transform diagnostics.
Detecting diseases in asymptomatic individuals is a game-changer. It enables timely interventions and significantly improving patient outcomes.
The SiMoT platform aligns with the World Health Organization’s benchmarks for point-of-care testing (POCT), offering unparalleled sensitivity and specificity in a portable, cost-effective format.
As part of the SiMBiT project, SiMoT is capable of detecting both protein and DNA single markers in just 0.1 mL of biological fluid.
This level of precision makes it an ideal tool for early disease screening, even in individuals showing no symptoms.
SiMoT offers diagnostic accuracy on par with molecular tests, achieving an impressive 96-99% sensitivity and specificity.
This exceptional performance was demonstrated in a pre-clinical trial for pancreatic cancer. No false negatives were reported among more than 70 patients.
Such results highlight the potential of SiMoT to revolutionize early disease detection.
The SiMoT platform is undergoing rigorous evaluation in an in-vivo diagnostic clinical trial involving 1,500 assays of blood and urine samples from oncology patients.
This trial aims to advance the technology from TRL5 to TRL7, bringing it closer to widespread clinical adoption.
Additionally, the SiMBiT project’s development of a 96-bioelectronic sensor array for multiplexed detection has been validated in clinical trials for early cancer screening, further demonstrating its potential.
By attending this webinar, you will:
This webinar is your chance to learn from one of the leading minds in the field, Luisa Torsi.
You will gain insights into a technology that promises to redefine diagnostic capabilities.
Whether you’re a healthcare professional, researcher, or simply interested in cutting-edge innovations, this session is not to be missed.
Don’t miss this opportunity to be part of a transformative discussion on the future of healthcare.
ILM Guide 2026/27